My NCBISign In
Are triple-negative tumours and basal-like breast cancer synonymous?
Emad A Rakha, David SP Tan, William D Foulkes, Ian O Ellis, Andrew Tutt, Torsten O Nielsen, Jorge S Reis-Filho
Breast Cancer Res. 2007; 9(6): 404. Published online 2007 November 30. doi: 10.1186/bcr1827
PMCID:
PMC2246182
Full Text PDF–42K

Is Cited by the Following 15 Articles in this Archive:

Clinico-Pathological Characteristics of Triple Negative and Non Triple Negative High Grade Breast Carcinomas with and Without Basal Marker (CK5/6 and EGFR) Expression at a Rural Tertiary Hospital in India
Chidambharam Choccalingam, Lakshmi Rao, Sruti Rao
Breast Cancer (Auckl) 2012; 6: 21–29. Published online 2012 January 9. doi: 10.4137/BCBCR.S8611
PMCID:
PMC3273309
Abstract Full Text PDF–1.2M
Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts
Carsten Denkert, Bruno Valentin Sinn, Yasmin Issa, Berit Maria Müller, Andrea Maisch, Michael Untch, Gunter von Minckwitz, Sibylle Loibl
Breast Care (Basel) 2011 August; 6(4): 265–272. Published online 2011 August 29. doi: 10.1159/000331696
PMCID:
PMC3225210
Free in PMC on 2012/08/01
Triple-Negative Breast Cancer: Clinical and Histological Correlations
Zeinab Elsawaf, Hans-Peter Sinn
Breast Care (Basel) 2011 August; 6(4): 273–278. Published online 2011 August 26. doi: 10.1159/000331643
PMCID:
PMC3225211
Free in PMC on 2012/08/01
αB-Crystallin is a Novel Oncoprotein Associated with Poor Prognosis in Breast Cancer
Hae Sung Kim, Younok Lee, Young Ah Lim, Hee Joon Kang, Lee Su Kim
J Breast Cancer. 2011 March; 14(1): 14–19. Published online 2011 March 31. doi: 10.4048/jbc.2011.14.1.14
PMCID:
PMC3148513
Abstract Full Text PDF–1.2M
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy
Beate C. Litzenburger, Chad J. Creighton, Anna Tsimelzon, Bonita T. Chan, Susan G. Hilsenbeck, Tao Wang, Joan M. Carboni, Marco M. Gottardis, Fei Huang, Jenny C. Chang, Michael T. Lewis, Mothaffar F. Rimawi, Adrian V. Lee
Clin Cancer Res. Author manuscript; available in PMC 2012 April 15.
Published in final edited form as: Clin Cancer Res. 2011 April 15; 17(8): 2314–2327. Published online 2010 December 22. doi: 10.1158/1078-0432.CCR-10-1903
PMCID:
PMC3073089
Abstract Full Text PDF–4.4M Supplementary Material
Treatment options for patients with triple-negative breast cancer
Rafael Santana-Davila, Edith A Perez
J Hematol Oncol. 2010; 3: 42. Published online 2010 October 27. doi: 10.1186/1756-8722-3-42
PMCID:
PMC2987865
Abstract Full Text PDF–409K
Triple-negative breast cancer
Reinaldo D Chacón, María V Costanzo
Breast Cancer Res. 2010; 12(Suppl 2): S3. Published online 2010 October 22. doi: 10.1186/bcr2574
PMCID:
PMC2972557
Abstract Full Text PDF–271K
CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
Xinhui Wang, Takuya Osada, Yangyang Wang, Ling Yu, Koichi Sakakura, Akihiro Katayama, James B. McCarthy, Adam Brufsky, Mamatha Chivukula, Thaer Khoury, David S. Hsu, William T. Barry, H. Kim Lyerly, Timothy M. Clay, Soldano Ferrone
J Natl Cancer Inst. 2010 October 6; 102(19): 1496–1512. doi: 10.1093/jnci/djq343
PMCID:
PMC2950168
Abstract Full Text PDF–1.9M Supplementary Material
Synergistic chemosensitivity of triple-negative breast cancer cell lines to PARP inhibition, gemcitabine and cisplatin
Kedar Hastak, Elizabeth Alli, James M. Ford
Cancer Res. Author manuscript; available in PMC 2011 October 15.
Published in final edited form as: Cancer Res. 2010 October 15; 70(20): 7970–7980. Published online 2010 August 26. doi: 10.1158/0008-5472.CAN-09-4521
PMCID:
PMC2955854
Abstract Full Text PDF–1.8M Supplementary Material
Association of invasion-promoting tenascin-C additional domains with breast cancers in young women
David S Guttery, Rachael A Hancox, Kellie T Mulligan, Simon Hughes, Sinead M Lambe, J Howard Pringle, Rosemary A Walker, J Louise Jones, Jacqueline A Shaw
Breast Cancer Res. 2010; 12(4): R57. Published online 2010 August 2. doi: 10.1186/bcr2618
PMCID:
PMC2949648
Abstract Full Text PDF–1.0M Supplementary Material
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
Alfonso Sánchez-Muñoz, Elena Gallego, Vanessa de Luque, Luís G Pérez-Rivas, Luís Vicioso, Nuria Ribelles, José Lozano, Emilio Alba
BMC Cancer. 2010; 10: 136. Published online 2010 April 13. doi: 10.1186/1471-2407-10-136
PMCID:
PMC2868051
Abstract Full Text PDF–1.9M
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani, Sibylle Loibl, Berit M Müller, Marc Roller, Carsten Denkert, Martina Komor, Karsten Schlüns, Jens Uwe Blohmer, Jan Budczies, Bernd Gerber, Aurelia Noske, Andreas du Bois, Wilko Weichert, Christian Jackisch, Manfred Dietel, Klaus Richter, Manfred Kaufmann, Gunter von Minckwitz
Breast Cancer Res. 2009; 11(5): R69. Published online 2009 September 16. doi: 10.1186/bcr2363
PMCID:
PMC2790846
Abstract Full Text PDF–795K Supplementary Material
Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
David W Miles
Breast Cancer Res. 2009; 11(4): 208. Published online 2009 August 28. doi: 10.1186/bcr2237
PMCID:
PMC2750099
Abstract Full Text PDF–87K
Does vimentin help to delineate the so-called 'basal type breast cancer'?
Renata U Kusinska, Radzislaw Kordek, Elzbieta Pluciennik, Andrzej K Bednarek, Janusz H Piekarski, Piotr Potemski
J Exp Clin Cancer Res. 2009; 28(1): 118. Published online 2009 August 20. doi: 10.1186/1756-9966-28-118
PMCID:
PMC2738661
Abstract Full Text PDF–1.0M
Are triple-negative tumours and basal-like breast cancer synonymous? Authors' response
Bas Kreike, Marc J van de Vijver
Breast Cancer Res. 2007; 9(6): 405. Published online 2007 December 17. doi: 10.1186/bcr1832
PMCID:
PMC2246186
Full Text PDF–36K
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk